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Values of Sleep/Wake, Activity/Rest, Circadian Rhythms, and
Fatigue Prior to Adjuvant Breast Cancer Chemotherapy
Ann M. Berger, PhD, RN, AOCN, FAAN, Lynne A. Farr, PhD, Brett R. Kuhn, PhD, CBSM,
Patricia Fischer, BSN, RN, CCRC, and Sangeeta Agrawal, MS
University of Nebraska Medical Center, Omaha, NE
Abstract
Fatigue is the most prevalent and distressing symptom experienced by patients receiving adjuvant
chemotherapy for early stage breast cancer. Higher fatigue levels have been related to sleep
maintenance problems and low daytime activity in patients who have received chemotherapy, but
knowledge is sparse describing these relationships prior to chemotherapy. The Piper Integrated
Fatigue Model© guided this study, which describes sleep/wake, activity/rest, circadian rhythms and
fatigue, and how they inter-relate in women with Stage I, II or IIIA breast cancer during the 48 hours
prior to the first adjuvant chemotherapy treatment. The present report describes these variables in
130 females, mean age = 51.4 years; the majority were married and employed. Subjective sleep was
measured by the Pittsburgh Sleep Quality Index (PSQI) and fatigue was measured by the Piper
Fatigue Scale (PFS). Wrist actigraphy was used to objectively measure sleep/wake, activity/rest, and
circadian rhythms. Mean PSQI score was 6.73 ±3.4, indicating poor sleep. Objective sleep/wake
results were within limits of normal (WNL) established for healthy individuals, except for the number
and length of night awakenings. Objective activity/rest results were WNL except for low mean
daytime activity. Circadian rhythm mesor was 132.3(24.6) and amplitude was 97.2(22.8). Mean PFS
score was 2.56 ±2.0, with 72% reporting mild fatigue. There were significant relationships between
subjective and objective sleep, but no consistent patterns. Higher total and subscale fatigue scores
were correlated with most components of poorer subjective sleep quality (r= 0.25 to 0.42, P = <0.005).
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Introduction
Cancer-related fatigue (CRF) associated with antineoplastic therapy can have a profound
impact on an individual’s life, with significant physical, emotional, social, and economic
consequences that may persist for months or years after completing treatment (1). CRF has
been defined by the National Comprehensive Cancer Network (p. FT-1) as “a distressing,
persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatment that
is not proportional to recent activity and interferes with usual functioning” (2). Among the
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many factors that have been found to be associated with CRF are the presence and severity of
anxiety, pain, lower sleep quality, physical inactivity, and poor performance status (1). Models
of CRF have linked disturbed sleep/wake patterns with fatigue (3) and models of impaired
sleep have proposed that fatigue is an expected outcome of either restricted total sleep time or
fragmented sleep during the night (4).
Previous studies in breast cancer patients provide limited information about the relationship
between CRF and sleep prior to chemotherapy. Determining results from a large sample may
provide information that will allow comparison across studies of CRF and sleep, and to clarify
the effects of interventions designed to reduce CRF and improve sleep. Several randomized
controlled trials, including one described in this article, are currently underway that test
interventions to modify CRF by promoting quality sleep and increasing activity (5). Knowledge
of the relationship between CRF and sleep is enhanced when studies include both subjective
and objective measures.
Actigraphy involves the use of a portable device to record movement over time in the format
of activity counts. The size of a man’s wristwatch, the device is most commonly placed on the
non-dominant wrist to objectively measure sleep/wake, activity/rest, and circadian activity
rhythms (6). Fairly consistent terms have been reported in the literature to represent night sleep/
wake variables (6), but there has been less consistency in reporting day activity/rest variables
and circadian activity rhythms (7,8). Terms suggested by teams that participated in either a
National Cancer Institute (NCI) sponsored State of the Science Conference on Sleep/Wake
Disturbances in People with Cancer and their Caregivers (8) or an expert panel that developed
consensus recommendations for a standard set of research assessments in insomnia (9) are
reported in this paper. Twenty studies were found that reported results of the use of actigraphy
to measure sleep/wake, activity/rest, and/or circadian rhythms in adult cancer patients. Almost
all studies included samples of breast (10–17) or colo-rectal cancer patients (18–24); other
samples included adults with early and advanced lung cancer (25–27); bone metastasis (28);
childhood brain tumor cancer survivors (29), or a variety of cancers (30). Only two of the 20
studies focused on sleep/wake, activity/rest, circadian rhythms, and fatigue prior to the first
adjuvant breast cancer chemotherapy treatment (10,15). This type of chemotherapy treatment
is given after the main tumor has been removed and any remaining cancer is in small amounts
(microscopic metastases).
Ancoli-Israel et al. (10) reported patterns for 72-hrs prior to chemotherapy and found that
women (n=73) reported moderate fatigue and disturbed sleep that was verified by actigraphy
results. Total sleep time while in bed at night was 6.0 hrs and 76% of the time spent in bed at
night was spent asleep, both of which are below normal (8). Time awake after sleep onset
(WASO) was 1.8 hr/night. This was much longer than the 30 minutes (min) considered normal.
These data provided subjective and objective evidence of sleep disturbances in women prior
to chemotherapy.
In another study, Berger et al. (15) found that women (n=24) reported mild fatigue (2.1±2.0
on a 0–10 scale) and actigraphs showed some sleep variables were already disturbed 48-hrs
prior to chemotherapy. Total rest time in a 24-hour period, defined as total time in bed (min)
plus napping during the day (min) minus sleep latency and WASO (min), was 8.2 hrs. Sleep
efficiency was 86%. Both were within normal limits (WNL) for healthy people (8). However,
mean WASO was 1.2 hrs/night (mean total time in bed was 9.0 hrs.) and mean number of
awakenings during the sleep period was 9.8 ±6.3 (higher than the normal 2 to 6 times/night).
These objective results indicate major sleep maintenance problems prior to adjuvant
chemotherapy.
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A better understanding of sleep/wake, activity/rest, and circadian rhythms and their relationship
to other factors such as fatigue will be enhanced by examining a large sample of women with
breast cancer prior to chemotherapy. Therefore, the purpose of this paper is to provide a
description of the values of sleep/wake, activity/rest, circadian activity rhythms, and fatigue;
and how they inter-relate in women with Stage I, II or IIIA breast cancer during the 48 hours
prior to the first adjuvant chemotherapy treatment.
Methods
The present study is an analysis of baseline data from our Fatigue and Breast Cancer Study
(FBC), which has enrolled 219 women with stage I, II, or IIIA breast cancer who received
surgery and then adjuvant anthracycline-based chemotherapy. Participants in the experimental
arm of the study are coached to develop and adhere to an “Individual Sleep Promotion Plan”©
(ISPP). Participants assigned to the control arm receive equal time and attention and
information about healthy eating topics. Details of the pilot study are found elsewhere (14–
15). The Piper Integrated Fatigue Model© was the conceptual framework selected for the study
(3). This model proposes that 14 biochemical, physiologic, and psychosocial patterns are the
factors most likely to influence fatigue. Sleep/wake and activity/rest patterns were selected
from the model to determine their relationship to fatigue prior to chemotherapy.
Eligibility criteria included adults ages 19 years and older diagnosed with stage I–IIIA breast
cancer for the first time. Patients had undergone surgery and were scheduled to receive
anthracycline-based adjuvant chemotherapy. Karnofsky score was equal to or higher than 60,
and they were able to complete the research instruments. Exclusion criteria included co-morbid
diagnosis of chronic fatigue syndrome, unstable congestive heart failure, chronic obstructive
pulmonary disease, insulin-dependent diabetes, neuromuscular disease, sleep apnea, abnormal
thyroid function, chronic steroid therapy, or working a job with rotating or permanent night
shifts. The setting for this study was a mid-sized Midwestern city in the United States.
Participants received chemotherapy at several local outpatient medical oncology clinics. Both
subjective and objective measures of sleep/wake and activity/rest were obtained; circadian
rhythms were only determined by objective measurement. As a subjective phenomenon, fatigue
can only be ascertained by self-report, and was assessed in four subscales to determine mild,
moderate, and severe fatigue experiences.
Subjective Sleep/Wake
The Pittsburgh Sleep Quality Index (PSQI) takes less than 10 minutes to complete and was
administered on Day -2 prior to chemotherapy. This paper-and-pencil questionnaire measures
subjective sleep quality during the previous month (31). Responses to the 19 items are grouped
into seven components measuring sleep quality, sleep latency, sleep duration, habitual sleep
efficiency, sleep disturbances, sleeping medication use, and daytime dysfunction. These
components are weighted equally on a 0–3 scale, with a global PSQI score ranging from 0–
21. Higher scores indicate more severe complaints and a greater decrease in sleep quality. In
women with breast cancer, Cronbach’s alpha for the global PSQI was 0.80 and was 0.82 in
this study. Evidence for construct validity has also been demonstrated. A global PSQI score
above 5 has been found to have a sensitivity of 89.6% and a specificity of 86.5% in
differentiating good from poor sleepers. A cutoff score of 8 was found to discriminate poor
sleep quality in cancer patients (32).
Objective Sleep/Wake, Activity/Rest and Circadian Rhythms
Octagonal Motionlogger™ Actigraphs (Ambulatory Monitoring, Inc, Ardsley, NY) were worn
continuously for 48-hrs during usual daily activities. One-minute epochs were used to measure
sleep/wake, activity/rest, and circadian rhythms. Six sleep/wake and five activity/rest variables
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were selected that were identified by either an NCI-sponsored conference (8) or an expert panel
that recommended a standard set of research assessment in insomnia (9). Four circadian rhythm
variables were chosen: mesor (24-hr rhythm-adjusted mean activity movements); amplitude
(measure of the extent of rhythmic change or range of activity and rest values over 24-hrs);
acrophase (time of the peak in the 24-hr cycle); and goodness of fit (measure of robustness and
consistency of the rhythm) (33). Days of the week of monitoring varied based on the day of
the week of chemotherapy. The unit contains a piezoelectric linear accelerometer, a
microprocessor, and 2 MB memory. Actigraphy offers a useful, noninvasive method of
objectively quantifying actual movement over time. It is an important index of sleep/wake and
activity/rest in natural settings, such as home or military fields of operation, and it is a valuable
and valid addition to diary information (6,7). The sensitivity of the accelerometer has been
optimized to collect high quality sleep/wake data from the wrist actigraph (34–36).
Advantages of actigraphy include that it provides 24-hrs continuous, direct measurement of
movement and indirect measurement of sleep. Actigraphy is sensitive and precise compared
to self-report. It is user-friendly to wear, small, portable, light-weight, and comfortable. Scores
can be quickly obtained using algorithms that correlate with polysomnography in normal adults
at greater than 90%, the gold standard for cortical activity measures of wake and sleep stages
(6).
Fatigue
The Piper Fatigue Scale (PFS) (37) measures subjective cancer-related-fatigue (CRF). The
scale takes 2 to 5 minutes to fill out and was completed on Day -2 prior to chemotherapy. The
PFS total score contains 22 items divided into four subscales of subjective fatigue: behavioral/
severity (six items), sensory (five items), cognitive/mood (six items), and affective meaning
(five items). Each item is anchored by two descriptors (e.g., strong versus weak), and
participants circle a number from 0–10 that best describes their fatigue experience on that day.
Total and subscale mean scores were obtained by summing the individual items of each
subscale or total score and dividing by the number of items in the subscale or total score. Internal
consistency of the total scale and the subscales range from alphas of 0.92–0.98 across numerous
and diverse studies and was 0.95 and 0.92–0.95 in this study. Content and concurrent validity
estimates have been reported in cancer patients. Ranges of scores have been divided into mild
(0–3.99), moderate (4.0–6.99) and severe (7.0–10.0) to report results of this study.
Procedures
The study was approved by the local Scientific Review Committee for proposals involving
cancer patients and the Institutional Review Board. All eligible patients were invited to
participate in the study. Research nurses met the participants at their home or mutually
agreeable place. The research nurse followed the study protocol to obtain informed consent,
perform randomization stratified by site, sleep status history (good versus poor sleeper per item
#6 on PSQI), number of chemotherapy treatments planned (four or more than four), and deliver
the appropriate intervention.
Each participant received a full orientation to the study. Instructions were given for completing
questionnaires and continuously wearing the actigraph beginning at the time they got out of
bed on Day -2 prior to chemotherapy until they rose from bed on Day +7 after chemotherapy.
Data from Days -2 and -1 (48-hrs prior to chemotherapy) will be reported here. Since
chemotherapy treatments were given during the week, the 48-hrs of data collection could have
occurred on any two-day periods except Thursday-Friday and Friday-Saturday. The actigraph
event marker and the daily diary responses were used to discriminate wake from sleep times
when setting the intervals prior to the analysis.
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Plans for analysis of the questionnaires included computing the means, standard deviations
and ranges. Spearman rank correlations were performed between variables. SPSS version 13
and SAS version 9.1 programs (38,39) were used for data management. All actigraphy data
files were handled using the Action 4© software version 1.13 user’s guide to obtain sleep/
wake, activity/rest, and circadian rhythm variables results (40). Because of the limited time
available for the participant and research nurse to meet prior to chemotherapy, it was
determined that actigraphy day data met criteria for inclusion if the research nurse met the
participant and started data collection by 1:00 p.m. on the first day. Data were included in the
analysis if they contained at least one 24-hrs day/night cycle out of the desired 48-hrs of data
collection. Out of 128 women with night actigraphy data, 11 (8.6%) had data from one night
and 117 (91.4%) had data from two nights. Of the 130 subjects with day actigraphy data, 37
(28.5%) had data from one day and 93 (71.5%) had data from two days. About two-thirds of
the women put the actigraph on at or before 9:00 am on the first day.
Actigraphy files in zero-crossing-mode (ZCM) were analyzed using the Cole-Kripke algorithm
in Action 4© by two of the authors (AB & PF), who had established inter-rater reliability
agreement greater than 80% on more than 50 files of both good and poor sleepers. The file was
first scanned for missing data and if more than four hours of day data or two hours of night
data were missing from each interval, that day or night was not used in the analysis. Time limits
were set for the 48-hr period and automatic sleep scoring was performed. The file was reviewed
and intervals were individually set for each day and night period using, in order of priority as
decision guides, the event marker, diary data, sleep channel data, and cascading movement
counts. The Action 4© user’s guide assisted in analyzing data and generating sleep/wake,
activity/rest, and circadian rhythms (40). Cosinor analysis fitted a cosine curve to the wrist
activity data using a least-squares cosinor regression model to determine circadian rhythms
(33).
This report includes 130 participants enrolled into the study from April, 2003 to November,
2005. During that 31-month period, 432 patients were screened, 175 consented, and 26
withdrew after consenting. Of the remaining 149 participants, 130 had adequate data for
analysis. Table 1 displays the sample’s demographic characteristics.
Results
Subjective sleep ratings as measured by the PSQI total and components are displayed in Table
2. The mean total score prior to chemotherapy (6.61±3.42) was higher than the upper limit for
normal sleep but lower than the proposed cut-off for cancer patients (32). Among the
components, the sleep disturbance subscale had the highest score, with all participants reporting
sleep maintenance insomnia once or twice a week. Fifty-seven percent of participants’ total
score was higher than 5 and 26% of participants’ total score was higher than 8, reflecting
subjectively poor sleep during the month prior to treatment.
Objective sleep/wake, activity/rest, and circadian rhythms values obtained by actigraphy are
shown in Table 3. Sleep/wake variables include: sleep-onset latency (min), wake after sleep
onset (WASO; min), number of awakenings (number), total sleep time (at night after sleep
onset; min/hrs), and sleep efficiency (after sleep onset). Percent wake night is also included
and is preferred over traditional sleep laboratory measures of sleep efficiency because sleep
efficiency includes sleep latency, or time to fall asleep after the lights are out, which is less
reliable when using actigraphy (41). Mean sleep/wake variables were WNL for all values
except number of awakenings and WASO minutes.
Objective activity/rest variables obtained during the day include: daytime activity (count/min),
total sleep time (min), total wake time (min), sleep percent day, and wake percent day. Mean
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values for daytime activity counts/min (188.4±5.9) were at the low end of the normal range
(185–245 counts/min) indicating low activity during the two days prior to chemotherapy
(42). Total sleep time and day sleep percent were WNL.
Circadian rhythms obtained by actigraphy include: mesor, amplitude, acrophase, and goodness
of fit (GOF). These values are based on 48 or fewer hours of recording and may not be as
accurate as 72 hour recordings. The mean mesor was 132.25(24.5), or 93% of the value of
138.20± 8.38, and the amplitude was 97.18 (22.8), or 86.5% of the value of 112.35±4.93,
established by Farr and Boen using mid-life women scheduled for elective surgery (11,43).
Acrophase and GOF values were WNL at 12:59 and 0.62±.11.
Perceived fatigue ratings prior to chemotherapy are shown in Table 4. Total and subscale PFS
scores were in the mild range with a mean of 2.56±2.0 (0 to 10 scale). While 72% of the
participants reported mild fatigue, 27 % reported moderate fatigue, and 1% reported severe
fatigue. The cognitive/mood subscale (3.30±2.4) was the fatigue subscale reported as most
affected prior to chemotherapy.
Significant correlations between subjective and objective sleep/wake, activity/rest, circadian
rhythms, and fatigue are displayed in Table 5. Regarding fatigue and subjective sleep, higher
fatigue total scores were correlated with poorer sleep total scores (r = 0.36, P< 0.0001). Higher
total and subscales fatigue scores were correlated with all components of poorer sleep except
sleep duration and habitual sleep efficiency (Table 6). Higher fatigue scores were most strongly
correlated with the daytime dysfunction PSQI component (P<0.001).
When examining fatigue and objective measures of sleep/wake, activity/rest and circadian
rhythms, only acrophase was significantly related with higher total and behavioral/severity,
cognitive/mood, and affective meaning subscales scores. This means that those who got up
and going later in the morning reported higher fatigue.
Tests of the associations between subjective and objective measures of sleep/wake found that
the subjective PSQI total scores were not correlated with any of the objective sleep/wake
variables. A few significant correlations were found between subjective PSQI sleep
components and objective sleep/wake variables, including shorter perceived sleep duration and
higher reported sleep disturbances with higher number of WASO minutes. Self-identified use
of sleeping medications was related to higher sleep efficiency. In contrast, PSQI total scores
reflecting poorer sleep were related to all of the objective activity/rest variables representing
lower daytime activity and time awake (P<0.001 to P< 0.01). In addition, higher total PSQI
scores and the components of sleep quality, sleep latency, and habitual sleep efficiency were
correlated with lower mesor (P<0.001 to P< 0.01). Longer subjective sleep latency was the
only component associated with lower amplitude (P<0.05).
Discussion
The current study was undertaken to further establish values for sleep/wake, activity/rest,
circadian rhythms, and fatigue and how they inter-relate in women with Stage I, II or IIIA
breast cancer prior to the first adjuvant chemotherapy treatment. Findings provide an indication
of expected values for comparison to other samples of women in studies examining these
variables and their inter-relationships. These values also provide an important benchmark for
interpreting any results of intervention studies to reduce CRF. Findings support the linkages
posited in models between disturbed sleep/wake patterns and fatigue (3,4).
Results confirm the sleep maintenance problems and mild fatigue experienced by women with
breast cancer even before receiving chemotherapy. Low daytime activity may be independent
or dependent of the prior nights’ sleep. Recognition that amplitude was almost 15% more
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dampened than in the healthy population of mid-life women scheduled for elective surgery
studied by Farr and Boen (11,43) generates hypotheses about the inter-relationships between
activity rhythm variables and fatigue. Disrupted sleep, low daytime activity, and/or a dampened
range of activity over 24-hr periods is likely to contribute to perceptions of mild fatigue prior
to chemotherapy and moderate to severe fatigue after chemotherapy. While it has been difficult
to untangle the mechanisms influencing CRF, these findings show it to be related to sleep/wake
and activity/rest at this point in the treatment and not to be solely a result of chemotherapy.
It should be noted that these values obtained prior to chemotherapy do not represent a true
baseline because they do not reflect patterns of sleep/wake, activity/rest or circadian rhythms
of otherwise healthy middle-aged women. Nor do they represent a profile that should be the
goal for interventions designed to improve sleep, reduce fatigue, and promote entrainment of
circadian rhythms. They reflect the pathophysiological insult, emotional stress, and decision-
making burden experienced by women at this point in the disease and treatment trajectory.
However, it should be noted that more disturbed sleep per actigraphy may not be as highly
correlated with polysomnography (36).
These findings support Ancoli-Israel et al.’s suggestion that sleep is already disturbed and
fatigue is already present prior to chemotherapy (10). We are currently testing the ISPP©
intervention designed to reduce fatigue by increasing day activity and improving sleep and
circadian rhythms during and following chemotherapy. Patients may benefit from this
intervention during chemotherapy, but are likely to require earlier introduction to the
intervention in the cancer trajectory for maximum symptom management based on our initial
findings from this study. We currently do not know whether disrupted sleep/wake, activity/
rest, circadian rhythms, and higher fatigue are related to the effects of the cancer, the stress of
diagnosis, recent surgery, mood disturbances, and/or the anticipation of chemotherapy and its
impact on quality of life.
The current results can be compared to those in two prior studies. Ancoli-Israel et al. (10) and
Berger et al. (15) both reported more WASO time than was found in this sample. The range of
mean values reported in this study was 1.0 hr and was from 1.2 to 1.8 hrs spent awake at night
in the prior studies. Total sleep time while in bed at night was 37 min longer in this sample
(6.6 hrs) than in Ancoli-Israel et al.’s study (6.0 hrs). Ancoli-Israel’s study did not provide
information on participants’ menopausal status for comparison, and that might explain the
differences.
There are several possible explanations for why the total rest time was shorter in the present
study than in Berger et al.’s study (15). Participants in the current larger sample had a total rest
time of 6.5 hrs compared to 8.2 hrs in the smaller sample. The difference might be due to the
number of participants who were employed at the time of year when data were collected. In
the current study, 78% were employed and data were collected throughout the year. In the
smaller study, 60% were employed and data were collected in fall and winter months. Other
possibilities include differences in sample size and the duration of actigraph monitoring
periods, which may reflect discrepancies in the number of week days versus weekend days
collected.
The PFS was used in Berger et al.’s small sample and with this larger sample. In both studies,
women reported mild fatigue (< 4.0) (15). Women reported moderate fatigue on the
Multidimensional Fatigue Symptom Inventory-Short Form (MFI) in the study by Ancoli-Israel
et al (10). A study comparing four cancer-related fatigue questionnaires, but not the PFS,
recommended that the MFI undergo additional testing with cancer patients because of concerns
regarding the construct validity of the instrument (44). Future comparisons that include both
instruments would assist in understanding findings of this and other studies.
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Lower daytime activity and increased nighttime restlessness have been found to be associated
with higher fatigue during chemotherapy (12). This relationship appears to exist even prior to
chemotherapy, although statistical significance was not reached. In both Berger et al.’s pilot
intervention study (15) and in the current study, sleep efficiency higher than 85% and mild
fatigue (<4.0) were reported. Ancoli-Israel et al.’s (10) descriptive study reported lower sleep
efficiency (76%) and moderate fatigue prior to chemotherapy. These variables will be tested
for their relationship at each treatment and at several selected times following the completion
of chemotherapy.
In the present study, higher levels of fatigue were correlated with poorer subjective sleep in
almost all components. Yet, no single objective sleep/wake variable was correlated with
subjective sleep. All objective activity/rest variables, representing lower daytime activity and
more day resting, were related to poorer subjective sleep. Lower mesor obtained by actigraphy
was also associated with poorer perceived sleep. These results are consistent with previous
findings that subjective and objective measures of sleep do not correlate, but rather complement
each other (45). One possibility for these findings in this study is that the participant responses
to the PSQI were in relation to sleep during the prior month, whereas the actigraphy recorded
sleep during a specific 48 hrs of time. The point worth noting here is that associations between
higher fatigue and poorer sleep are found prior to receiving chemotherapy.
There are advantages and disadvantages to the use of subjective and objective measures of
sleep/wake, activity/rest, and circadian rhythm patterns in persons with cancer. Subjective
instruments do not consistently correlate with objective measures; there may be missing data,
responses require retrospective recall, and responses are difficult to control for time of day of
completion of the instrument. Sleep diaries are not considered to be an accurate assessment,
but rather subjective perceptions of sleep, and were only used in this study to determine bed-
time and get-up times in order to create appropriate intervals for actigraphy analysis.
A limitation of objective data is that the actigraph may also have missing data related to
malfunctioning, getting wet, failing to initialize or download correctly, and/or battery failure,
which occurred only 1% of the time in this study. While the ideal study design would yield
actigraphy data for a full 72-hrs prior to chemotherapy in order to study circadian rhythms, in
addition to sleep/wake and activity/rest, it was not always feasible to recruit the participant to
the study in time to collect 48-hrs of data. We recognize that this time limitation restricts our
ability to perform accurate circadian rhythm analyses, including the ability to evaluate patterns
of sleep/wake and activity/rest and their stability over time (7). There are known limitations
with wrist actigraphy, including the reliability of the latency variable each night (35) and its
inability to distinguish between immobile sleep and waking that may lead to an inflated total
sleep time. Values for actigraphy data in healthy adult women are sparse in the literature and
only sleep/wake values have been reported in a group of 20–40 year olds (45). Descriptions of
procedures to set time limits and intervals, to handle missing data, and to establish inter-rater
reliability (when appropriate) are sparse in the literature and have lead to inconsistent analysis
of data files (46). Other instruments to measure activity may only be useful for collecting
information about day activity. Polysomnography is only useful for sleep stage measures and
is limited by higher cost than actigraphy and the artificial environment of a sleep laboratory.
In conclusion, these results for sleep/wake, activity/rest, circadian rhythms, and fatigue in a
large sample of women prior to the first adjuvant breast cancer chemotherapy treatment provide
values for comparison with future studies. Larger samples with 72 hours or more of data will
be needed in future research to provide normative data values. The current study confirms that
values obtained prior to chemotherapy are not a true baseline. Sleep maintenance problems,
low daytime activity, and/or lower circadian rhythms likely contribute to the perceptions of
mild fatigue prior to chemotherapy and moderate to severe fatigue after chemotherapy. To
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maximize fatigue management, patients may benefit from an intervention introduced prior to
cancer surgery that promotes night sleep, increases day activity, and entrains circadian rhythms.
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Table 1
Demographic Characteristics of the Sample Prior to Chemotherapy (n=130)
Variable Numbers Percent Range
Age Mean= 51.40+ 9.68 34–83 years




Employment Status Managers, professionals =51 40
Technical, sales, office, production, laborers =50 38
Homemaker, retired, unemployed =29 22
Hours of work: Mean=31.7 0–65 hours
Education Less than high school=5 4
High school graduate =23 18
Some college= 41 31.5
College graduate =41 31.5
Post college graduate=20 15
Ethnicity Asian = 1 0.8
African American = 6 4.7
Caucasian = 119 91.5
Hispanic = 4 3.0
Cancer Stage Stage I = 45 36
Stage II= 60 48
Stage IIIA= 20 16
Type of Surgery Lumpectomy = 60 46
Modified Mastectomy = 37 29
Modified Mastectomy with Reconstruction = 33 25
Menopause Status Stopped >12 months =63 51
Stopped 6–12 months ago =3 2
Irregular past 6 months =13 11
Regular past 6 months =45 36
Note: Missing data when numbers do not add up to 130.
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Table 2
Subjective Sleepa Prior to First Chemotherapy (n=130)









Total score (n=127) 0–21 6.61b 3.42
Sleep quality 0–3 1.0 0.68 25 (19) 85 (65) 20(15)
Sleep latency 0–3 1.11 0.93 37 (28) 54 (42) 39 (30)
Sleep duration 0–3 0.76 0.81 59 (46) 44 (34) 26 (20)
Habitual sleep efficiency 0–3 0.59 0.89 79 (62) 28(22) 20(16)
Sleep disturbances 0–3 1.55 0.57 0 (0) 64(49) 66(51)
Use of sleeping
medications
0–3 0.74 1.17 87(67) 13(10) 30(23)
Daytime dysfunction 0–3 0.88 0.57 28(22) 90(69) 12(9)
Total score (n=127) Mean score <=5 Mean score >5 Mean score >8
55(43) 72(57) 33(26)
Note: Missing data when numbers do not add up to 130.
SD = standard deviation.
a
Subjective sleep measured by Pittsburgh Sleep Quality Index (31)
b
Good sleeper < or = 5; poor sleeper >5 (28); poor sleeper with cancer >8 (32).
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Table 3
Actigraph for Sleep/Wake, Activity/Rest, and Circadian Rhythms Prior to Chemotherapy (n=128–130)
Variable Mean SD Range
Sleep/wake
Sleep-onset latency (min) 11.38 17.88 0–187
Wake after sleep onset (WASO) (min/hr) 62.49/1.04 66.01 0–427 min
Number of awakenings 9.70 5.47 0–27.5
Total sleep time (min/hr) 396.84/6.61 95.74 90.0–604.5
Sleep efficiency (percentage) 86.13 15.14 17.4–100
Percent Wake night 13.87 15.14 0–82.6
Activity/rest
Mean daytime activity 188.37 35.89 57.1–250.1
Total sleep time (min/hr) 64.17/1.07 57.79 0–285
Total wake time (min/hr) 829.72/13.83 133.53 71.5–1081
Sleep percent day 7.49 7.57 0–52.1
Wake percent day 92.51 7.57 47.9–100
Circadian rhythms
Mesor 132.25 24.56 52.2–187
Amplitude 97.18 22.80 26.4–145.7
Acrophase 12:59 - -
Goodness of Fit 0.62 0.11 0.3–0.88
SD = standard deviation.
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Table 4
Fatiguea,b and Distribution of Scores Prior to Chemotherapy (n=130)






Behavioral/severity 0–10 1.91 2.1 0–7.3 107 19 4
Sensory 0–10 2.58 2.3 0–9.6 91 33 5
Cognitive/mood 0–10 3.30 2.4 0–9.0 76 48 6
Affective meaning 0–10 2.56 2.1 0–7.8 91 37 2
Total score 0–10 2.56 2.0 0–8.0 93 35 2
a
Fatigue measured by Piper Fatigue Scale (37).
b
Descriptors for each item ranging from 0–10 to indicate none to severe.
c
Note: number of participants whose scores were within the range for each level.
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